Fusion Antibodies announce new senior hire to support Innovation

Fusion Antibodies welcome Jenna Hewitt as newly appointed R&D Director.

Fusion Antibodies, a specialist in the discovery and development of antibodies, has appointed Jenna Hewitt as R&D Director. This is a newly created position within Fusion Antibodies and represents the tremendous growth that the organisation has undergone and marks the start of an exciting new era as the company looks to further expand its services to best support its customers.

Jenna joins with over 13 years of experience working within the Biotechnology and Pharmaceutical industry, where she started as a development scientist for MedImmune/AstraZeneca before moving into research and development project management.

In her career she has managed a variety of projects, including an EU-funded biofuels development venture. Jenna also has extensive experience leading biologics projects as well as veterinary and human pharmaceuticals where she managed the whole product pipelines through development, clinical, regulatory and product launch.

“I am delighted to join the Senior Management Team at Fusion Antibodies” shared Jenna. “This is an extremely exciting time in the company’s development, and I look forward to working with the talented and innovative team to help the company achieve greater results for our employees, shareholders and customers.”

 Dr Richard Buick, CTO of Fusion Antibodies said

“We are excited to welcome Jenna to Fusion Antibodies. With this new position we will create an even more focused R&D process portfolio. The company has seen a steady increase in our client base and revenue over previous years and this will continue as we move forward.”

Richard continued;

“This role has been created to concentrate on ensuring an effective R&D process and commercialisation of new innovations. Jenna’s strong background in scientific research and development made her the ideal candidate to instil techniques that streamline and optimise our processes to improve efficiencies for our customers.”

Jenna concluded;

“I welcome this opportunity to contribute to an innovative and fast-moving company. My passion and commitment are in biologics and making a difference to improving human and animal health. In my first few days, I have quickly established that Fusion’s core focus is delivering exceptional quality and commitment to the customer. I am confident that our innovation will flourish and as a team, we will continue to bring forth new ideas to grow Fusion Antibodies portfolio of services that we can offer our customers.”

Fusion Antibodies